OncoMatch/Clinical Trials/NCT07324304
NWRD06 DNA Plasmid for HCC After Curative Resection.
Is NCT07324304 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies NWRD06 administered by electroporation for hepatocellular carcinoma (hcc).
Treatment: NWRD06 administered by electroporation — This is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma after curative resection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: GPC3 positive by immunohistochemistry
GPC3 positive confirmed by immunohistochemistry (IHC)
Disease stage
Required: Stage BCLC A, BCLC B, CNLC IB, CNLC IIA, CNLC IIB, CNLC IIIA (BCLC, CNLC)
Barcelona clinic liver cancer (BCLC) stage A/B or Chinese Hepatocellular carcinoma Stage (CNLC) Ib-IIIa
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: curative treatment — surgical resection or local ablation
Must have undergone curative treatment (surgical resection or local ablation) for HCC within 12 weeks prior to the first NWRD06 administration
Cannot have received: systemic anti-tumor therapy
Received any systemic anti-tumor therapy for HCC (including chemotherapy, molecular targeted therapy, bio-immunotherapy) within 28 days prior to screening
Lab requirements
Blood counts
Hemoglobin (Hb) ≥90 g/L; Platelet count (PLT) ≥75×10^9/L
Kidney function
Serum Creatinine (Scr) ≤1.5 × ULN, OR Creatinine Clearance ≥40 mL/min (if Scr >1.5 × ULN)
Liver function
Total bilirubin (TB) ≤3× ULN; ALT and AST ≤5×ULN; Plasma albumin ≥30g/L; Child-Pugh score A/B (≤7)
Adequate organ function within 1 week prior to the first dose: 1) Blood routine: Hemoglobin (Hb) ≥90 g/L; Platelet count (PLT) ≥75×10^9/L; 2) Liver: Total bilirubin (TB) ≤3× ULN; ALT and AST ≤5×ULN; Plasma albumin ≥30g/L; 3) Coagulation: INR ≤2.3. 4) Renal: Serum Creatinine (Scr) ≤1.5 × ULN, OR Creatinine Clearance ≥40 mL/min (if Scr >1.5 × ULN). Child-Pugh score A/B (≤7)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify